One method being studied is immunoglobulin replacement therapy, which involves the administration of human normal immunoglobulin through an intravenous line, meaning it is delivered directly into a vein. The other method is antibiotic prophylaxis, which is the use of medications to prevent infections before they occur. The medications used for comparison in this study include amoxicillin trihydrate, sulfamethoxazole, trimethoprim, bromhexine hydrochloride, levofloxacin, amoxicillin sodium, and azithromycin.

Participants in the study will be assigned to one of the two prevention methods. During the follow-up period, which lasts for 12 months, the occurrence of infections will be monitored. This includes looking for recurrent infections that require treatment or severe infections that lead to a hospital stay.

The purpose of the study is to compare how well these two treatment approaches work and to check their safety in older adults or those who are not strong enough for standard treatment. The study will measure how long participants live without their disease getting worse and will also look at side effects and quality of life. The first part of the study will test the safety of the shorter R-mini-CHOP treatment followed by AZD0486 in a small group of participants to make sure the dose is appropriate.

Participants will be randomly assigned to receive either six cycles of R-mini-CHOP or two cycles of R-mini-CHOP followed by treatment with AZD0486. During the study, participants will have regular check-ups, blood tests, and scans to monitor their disease and overall health. The treatment period can last up to several months, and participants will continue to be followed for several years after treatment ends to see how well the treatment worked over time.

The purpose of the study is to test the safety of different doses of Allo-QuadCAR01-T in the early phases and to find the best dose to use. In the later phase, the study aims to see how well this treatment works at controlling or eliminating the cancer. The study is divided into three parts. In the first part, called Phase Ia, different dose levels of the treatment will be tested to see if they are safe and well-tolerated. In Phase Ib, the treatment will continue to be tested for safety and the researchers will confirm the recommended dose for the next phase. In Phase II, the study will focus on measuring how effective the treatment is at making the cancer respond or disappear.

Patients in this study will need to have their disease confirmed by tissue examination and must have received at least two previous treatments, or be unsuitable for standard treatments, or have chosen not to receive them. Before receiving Allo-QuadCAR01-T, patients will undergo tests to make sure they meet the requirements, including having their tissue type matched to available treatment batches. The treatment itself is given after a short course of chemotherapy to prepare the body. During and after the treatment, patients will be monitored closely for side effects and to see how well the cancer responds. This monitoring includes blood tests, imaging scans, and other assessments to track the cancer and the immune cells over time.

The purpose of this study is to determine if this new cell therapy treatment is safe to use and if it works effectively against these blood cancers. The treatment is given as an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. This is a combined Phase 1 and Phase 2 study, where Phase 1 focuses on finding the right dose of the treatment, and Phase 2 examines how well the treatment works.

The treatment involves taking some of the patient’s own immune cells, modifying them in a laboratory to recognize and attack cancer cells, and then returning them to the patient through an infusion. After receiving the treatment, patients will be monitored for side effects and to see how their cancer responds to the therapy. The study specifically looks at patients whose cancer cells have a particular genetic marker called HLA-B*07:02.

The purpose of the study is to understand how CD8+ T-cells are distributed in the body and how they interact with the cancer both before and after the CAR T-cell therapy. This is done by using the PET imaging technique to capture images of the body and analyze the presence and activity of these immune cells. The study aims to see how the distribution of these cells might relate to the effectiveness of the CAR T-cell therapy in treating the lymphoma.

Participants in the study will receive the tracer injection and undergo PET imaging at different stages of their treatment. The study will monitor the uptake of the tracer in both normal tissues and tumor areas to gather information on how the immune cells are behaving. This information could help improve understanding of the treatment process and potentially lead to better outcomes for patients with large B-cell lymphoma.

The purpose of this study is to evaluate the safety and effectiveness of this new treatment. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor how the body responds to the treatment and any side effects that may occur. The trial will also compare the new treatment to existing treatments to see if it offers any advantages.

In addition to HSP-CAR19M, other medications used in the study include Beneflur (containing fludarabine phosphate), Genoxal (containing cyclophosphamide monohydrate), RoActemra (containing tocilizumab), and Levact (containing bendamustine hydrochloride). These medications are used to prepare the body for the new treatment or to manage symptoms. Some participants may receive a placebo, which looks like the treatment but does not contain the active medicine. The study will continue until the end of 2025, with regular check-ups to assess the treatment’s impact on the cancer and the patient’s overall health.

The study is divided into two phases. In the first phase, different doses of IDP-121 will be given to patients to determine the highest dose that can be safely administered. This is known as the dose-escalation phase. In the second phase, the study will focus on how effective the recommended dose is in treating the cancers. This phase will look at how many patients respond to the treatment and how long the response lasts.

Throughout the study, patients will receive regular check-ups to monitor their health and the effects of the treatment. This includes checking vital signs, conducting physical exams, and performing various tests like blood tests and heart monitoring. The study aims to gather information on how the treatment affects the body and how long patients can live without the cancer getting worse. Safety and any side effects will also be closely observed to ensure the well-being of the participants.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

The purpose of this research is to determine how safe the medication is, how it moves through the body, and how effective it is in treating these types of cancer. The study is divided into two parts. In the first part, different doses of the medication will be tested to find the most appropriate amount. In the second part, researchers will evaluate how well the medication works in treating the cancer.

During the study, participants will take CYC140 once daily for 28-day cycles. The treatment will continue as long as it remains beneficial for the patient. Throughout the study, doctors will monitor patients’ health status and how their cancer responds to the treatment. Various medical assessments will be performed to track the progress of the treatment and ensure patient safety.

The medication being tested comes in the form of film-coated tablets that are taken by mouth. The purpose of this study is to determine how effective valemetostat tosylate is when used alone in treating these types of lymphoma. The treatment may continue for up to three years, depending on how well patients respond to the medication.

During the study, doctors will monitor how patients respond to the treatment by performing regular medical examinations and scans. They will specifically look at whether the cancer shrinks or disappears in response to the medication. The study will also track how long any positive responses to the treatment last and evaluate the safety of the medication.

The purpose of the study is to evaluate how effective this combination of treatments is for patients who are not eligible for a standard chemotherapy regimen known as R-CHOP. The study will involve a series of treatment cycles, where patients will receive the medications over a period of time. The study will monitor the patients’ response to the treatment, including how long they remain free from disease progression and their overall survival rates. The study will also look at the safety of the treatment and any side effects that may occur.

Throughout the study, patients will be closely monitored by healthcare professionals to ensure their safety and to assess the effectiveness of the treatment. The results from this study will help in planning future research and may lead to new treatment options for patients with aggressive B-cell lymphoma. The study aims to provide valuable information that could improve the care and outcomes for patients with this type of cancer.

The purpose of the study is to determine if adding Polatuzumab vedotin to the R-ICE regimen improves the time patients remain free from cancer events, which is referred to as event-free survival. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will follow participants over a period to monitor their response to the treatment and any side effects they may experience.

Throughout the study, researchers will collect information on various outcomes, such as how long patients remain free from cancer progression, the overall response to the treatment, and any side effects. The study will also look at the quality of life of participants during and after treatment. This research is important for understanding whether the addition of Polatuzumab vedotin can provide better outcomes for patients with relapsed or refractory DLBCL compared to the standard R-ICE treatment alone.

The study involves several treatments, including PHE885, YTB323, and Tisagenlecleucel. These treatments are given as a dispersion for infusion, which means they are administered directly into the bloodstream through an intravenous infusion. PHE885 uses a patient’s own T-cells that are engineered to target a specific protein on cancer cells called the B cell maturation antigen. YTB323 involves T-cells that are modified to target another protein known as CD19. Tisagenlecleucel is also a type of CAR T-cell therapy that targets cancer cells using a similar approach.

Throughout the study, researchers will monitor patients for any new health issues that may arise after receiving CAR T-cell therapy. This includes checking for new cancers, serious infections, neurological disorders, autoimmune conditions, and blood disorders. The study will also track the presence of the modified T-cells in the blood over time and observe any changes in the patient’s health status, such as relapse or progression of their condition. The study aims to provide valuable information on the long-term safety and effects of CAR T-cell therapy.

The purpose of the study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive a pre-treatment dose of Obinutuzumab before starting the combination therapy. The study will be conducted in different phases to determine the best dose and to observe how the body processes the medications. The study will also look at how well the treatment works in reducing the size of the tumors and controlling the disease.

Throughout the study, participants will be closely monitored for any side effects and how their bodies respond to the treatment. The study aims to find the most effective dose that can be safely given to patients. This research is important for developing new treatment options for people with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma and potentially improving their outcomes. The study is expected to continue until 2026, with the goal of gathering comprehensive data on the treatment’s safety and effectiveness.

Participants in this study will continue to receive Zanubrutinib in the form of capsules taken orally. The study is open-label, meaning both the researchers and participants know what treatment is being administered. The study will take place over an extended period, allowing researchers to gather information on the safety and effects of the treatment over time. Some participants may receive a placebo as part of the study design.

The main focus of the study is to monitor the safety of the treatment by observing any side effects or adverse events that occur. Additionally, researchers will assess how long patients remain free from disease progression, the duration of their response to the treatment, and their overall survival. This information will help determine the long-term benefits and risks of using Zanubrutinib for treating B-cell malignancies.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study is divided into two parts. In the first part, the focus is on understanding how the body processes Glofitamab and how well it works on its own. In the second part, the study looks at how Glofitamab works when combined with the R-ICE chemoimmunotherapy. The study will monitor participants for any side effects and measure how well the treatment is working against the cancer.

The trial aims to gather information on the safety and effectiveness of Glofitamab, both alone and in combination with other drugs, to see if it can help achieve a complete response, which means the cancer is no longer detectable. The study will also look at how long any positive effects last and how the treatment impacts overall survival. This research is important for developing new treatment options for young patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma.

The purpose of this study is to determine if the combination of Epcoritamab, Rituximab, and Lenalidomide can improve the rate of complete response, meaning the disappearance of all signs of cancer, compared to the standard treatment known as chemoimmunotherapy. Participants in the study will be randomly assigned to receive either the new combination treatment or the standard treatment. The study will monitor participants over a period of time to assess the safety of the treatments and any changes in the activity of the disease. The study will also look at other outcomes, such as progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and overall survival, which is the length of time from the start of treatment that patients are still alive.

Throughout the study, participants will receive their treatments either through subcutaneous injection, which is an injection under the skin, or intravenous infusion, which is an injection into a vein, depending on the medication. The study aims to provide valuable information on whether this new combination of treatments can offer a better outcome for patients with previously untreated Follicular Lymphoma compared to existing treatment options. Participants will be closely monitored for any adverse events, which are any unwanted effects of the treatment, to ensure their safety throughout the study.

The purpose of the study is to assess how well Axi-Cel works as a second-line therapy for patients who cannot undergo a procedure called autologous stem cell transplantation. This is a treatment option that uses a patient’s own stem cells to help recover from high-dose chemotherapy. The study will monitor the patients’ response to the treatment over a period of time, specifically looking at the complete metabolic response, which is a measure of how much the cancer has decreased or disappeared, at three months after receiving Axi-Cel.

Participants in the study will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will track the progress of the participants at various intervals to see how the treatment affects their cancer and overall health. The goal is to gather information on the effectiveness and safety of Axi-Cel in treating this type of lymphoma. The study is expected to continue until 2025, providing valuable insights into this promising treatment option.

The purpose of the study is to evaluate how well Odronextamab works in shrinking tumors and to assess its safety in patients. The study includes several subtypes of B-cell non-Hodgkin lymphoma, such as follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Patients participating in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the patients over a period of time to see how their cancer responds to the treatment and to check for any side effects.

Throughout the study, researchers will collect information on how the cancer responds to Odronextamab and any changes in the patients’ health. This information will help determine the effectiveness of the treatment and its potential as a new option for patients with B-cell non-Hodgkin lymphoma. The study aims to provide valuable insights into the treatment of this type of cancer and improve future care for patients. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

The purpose of the study is to evaluate how effective and safe JCAR017 is for patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive the treatment through an injection into a vein. The study will follow the participants over a period to observe how their cancer responds to the treatment and to monitor any side effects they may experience. Some participants may receive a placebo, which is a substance with no active treatment, to compare the effects of the actual treatment.

Throughout the study, various assessments will be conducted to measure the response of the cancer to the treatment, including imaging tests like PET-CT or CT scans. The study will also look at how long the treatment effects last, the overall survival of participants, and any changes in their quality of life. The safety of the treatment will be closely monitored to ensure the well-being of all participants. This study aims to provide valuable information on the potential benefits and risks of using JCAR017 for treating these types of lymphoma.

Participants in this study will continue to receive ibrutinib, which is taken in the form of a capsule. The study will monitor the participants’ health and any changes in their condition while they are on the medication. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study aims to ensure that ibrutinib remains safe and effective for those who have been using it and to understand its long-term impact on their health.

The study will take place over several years, allowing researchers to collect comprehensive data on the long-term use of ibrutinib. Participants will be regularly assessed to track any side effects or changes in their disease status. This information will help in understanding how ibrutinib can be used most effectively in treating these conditions and ensuring the well-being of those who rely on it for their treatment.

The purpose of the study is to evaluate the safety and effectiveness of UCART20x22 in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. The study is divided into two parts: the first part aims to find the best dose of the treatment, while the second part will further test the treatment’s safety and confirm the best dose. Participants will receive the treatment through an intravenous infusion, which means it will be administered directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and the treatment’s ability to control the cancer. The study will also involve other medications, such as Fludarabine and Cyclophosphamide, which are commonly used in cancer treatment. These medications help prepare the body to receive the cell therapy. The trial will continue for several years to gather comprehensive data on the treatment’s long-term effects and benefits.

The purpose of the study is to understand how safe and tolerable pembrolizumab is for children and to see how well it works against these cancers. Pembrolizumab is given as an infusion, which means it is delivered directly into the bloodstream through a vein. The study will monitor the children for any side effects and measure how their tumors respond to the treatment. Some children in the study may receive a placebo, which is a substance with no active medication, to compare the effects of pembrolizumab.

Participants in the study will receive regular assessments to track their health and the progress of their cancer. These assessments will help researchers determine the effectiveness of pembrolizumab in shrinking or controlling the tumors. The study aims to provide valuable information that could lead to better treatment options for children with these challenging types of cancer.

The purpose of the study is to assess how effective loncastuximab tesirine is in treating these conditions. The treatment is given as an infusion, which means it is administered directly into the bloodstream through a vein. Participants in the study will receive this treatment over a period of time, and their response to the treatment will be monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment.

Throughout the study, researchers will observe how the disease responds to the treatment, including whether it shrinks or disappears, and how long any positive effects last. They will also monitor the overall health and survival of the participants, as well as any side effects that may occur. The study aims to provide valuable information on the potential benefits and risks of using loncastuximab tesirine for these types of lymphoma.

The purpose of the study is to find out if AZD5492 is safe and how well it works when used alone or with other cancer treatments. Participants in the study will receive AZD5492 as an injection under the skin. The study will take place over a period of time, during which participants will be closely monitored for any side effects and to see how their cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, doctors will check for any changes in the participants’ health, including any side effects or improvements in their condition. The study aims to gather important information about the safety and potential benefits of AZD5492 for people with these types of blood cancers. This information will help determine if AZD5492 could be a useful treatment option in the future.

Participants in the study will receive either Acalabrutinib alone or in combination with Rituximab. The study will monitor the response of the lymphoma to these treatments over time. This involves regular check-ups and assessments to see how the disease is responding to the medication. The study is designed to gather information on the effectiveness and safety of the treatments, including any side effects that may occur.

The trial is open-label, meaning both the researchers and participants know which treatment is being administered. The study will continue until the estimated end date in 2028, allowing researchers to collect comprehensive data on the long-term effects of the treatments. Participants will be closely monitored throughout the study to ensure their safety and to gather detailed information on the impact of the treatments on their lymphoma.